03/12/2018
Marie Skłodowska-Curie Actions

I-Direct (ESR 10): "Nanoparticles for targeted delivery to tumours"

This job offer has expired


  • ORGANISATION/COMPANY
    INOCURE SRO
  • RESEARCH FIELD
    Biological sciencesOther
    ChemistryOther
  • RESEARCHER PROFILE
    First Stage Researcher (R1)
  • APPLICATION DEADLINE
    30/04/2019 00:00 - Europe/Brussels
  • LOCATION
    Czech Republic › Praha
    Netherlands › Groningen
  • TYPE OF CONTRACT
    Temporary
  • JOB STATUS
    Full-time
  • HOURS PER WEEK
    40
  • OFFER STARTING DATE
    01/06/2019
  • EU RESEARCH FRAMEWORK PROGRAMME
    H2020 / Marie Skłodowska-Curie Actions
  • REFERENCE NUMBER
    I-Direct 813871
  • MARIE CURIE GRANT AGREEMENT NUMBER
    813871

Keywords: checkpoint targeting, bispecific antibody, nanoparticles, surface modification, drug-delivery

 

1st Hosting institution: Location: InoCure, Prag, Czech Republic; Duration: 18 months

2nd Hosting institution: Location: UMCG, Groningen, Netherlands; Duration: 18 months

 

PhD-student position (3 years):

ESR 10 project will be focused on development of nanoparticles with peptide-based targeting moieties. The peptides will be developed using chemical/computational modelling. The peptides will be immobilized on surface of particles using click-chemistry, conjugation using EDC/NHS and layer-by-layer deposition. The particles will be optimized for delivery of therapeutic antibodies for cancer treatment. The particles with NIR dyes will be tested on animal models (mice) for localization to tumour site at the state of-the-art small animal imaging facility of the UMCG. The sequence of peptides will be modified to achieve maximal targeting and minimal uptake by the immune system or liver.

The PhD candidate will be working as part of an international consortium on their search for an immunotherapeutic approach to cancer treatment and will start their 3 year research project in InoCure s.r.o. (Prague, Czech Republic). The work in Prague will be performed for 18 months and will be focused on development of drug-delivery systems with cleavable linkers. Thereafter will the ESR join team of Prof. Bremer at University of Groningen for additional 18 months for testing of therapeutic efficacy on in vitro and in vivo models. This research project will end with a PhD thesis defense at the University of Groningen.

This project is part of a collaborative training network of 10 closely related projects in which PhD students will benefit from networking opportunities. This includes a multidisciplinary training programme with network-wide training events that will be provided to the candidates. Herewith, the PhD project will provide the candidate a unique opportunity to obtain knowledge/expertise on important facets of both academia and industry.

 

SEE THE OTHER 9 PhD POSITIONS AND WORK LOCATIONS OF I-DIRECT:

10 position(s) available at various locations (2 locations for each ESR, 18 months each)

ESR1: Development and preclinical validation of tumour-selective PD-1/PD-L1 immunotherapeutics and drug delivery systems

Netherlands/Czech Republic

ESR2: Cancer immunomodulation upon tumour-selective targeting of innate immune checkpoints

Netherlands/Germany

ESR3: Development, label free bioanalysis and preclinical validation of Adenosine-2A-Receptor (A2AR)-targeting bispecific antibodies

Germany/Netherlands

ESR4: Development of stimuli-sensitive particles for tumour-selective targeting of TIM-3/Galectin-9

Germany/Netherlands

ESR5: Targeted inhibition of novel immune checkpoints

Netherlands/Germany

ESR6: Development and characterization of antibody fusion proteins with tumour-restricted FcgR-independent co-stimulatory activity by targeting CD70

Germany/Czech Republic

ESR7: Development and characterization of antibody fusion proteins with tumour-restricted FcgR-independent co-stimulatory activity by targeting PD-L1

Germany/Czech Republic

ESR8: Development of stimuli-sensitive nanoparticles and in vivo evaluation of immune-stimulatory TNFSF ligand fusion proteins with FAP-restricted activity

Czech Republic/Germany

ESR9: Development of immunomodulatory Dual Signalling Proteins (DSPs) for cancer immunotherapy

Israel/The Netherlands

Required Research Experiences

  • RESEARCH FIELD
    Biological sciencesOther
  • YEARS OF RESEARCH EXPERIENCE
    1 - 4
  • RESEARCH FIELD
    ChemistryOther
  • YEARS OF RESEARCH EXPERIENCE
    1 - 4

Offer Requirements

  • REQUIRED EDUCATION LEVEL
    Biological sciences: Master Degree or equivalent
    Chemistry: Master Degree or equivalent
  • REQUIRED LANGUAGES
    ENGLISH: Excellent

Skills/Qualifications

Key Responsibilities:

  • Preparation of advanced drug delivery systems for targeting to tumour site
  • Validation of systems in vitro
  • Various encapsulation and surface modification activities
  • Optimization of the in vitro test conditions for a realistic simulation of the in vivo conditions
  • Management, presentation and publication of research data

Specific Requirements

  • Candidate is in the first four years of his/her research career and does not have a doctoral degree
  • Residence duration in the Czech Republic does not exceed 12 months in total within the last 3 years
  • MSc in material science, polymer science, chemistry, biomedicine, biotechnology, engineering or related
  • Collaboration skills, demonstrating agility and initiative. Ability to communicate effectively in English

Work location(s)
1 position(s) available at
INOCURE SRO
Czech Republic
Praha
11000
KLIMENTSKA 1652/36
1 position(s) available at
UMCG
Netherlands
Groningen
9713 GZ
HANZEPLEIN 1

EURAXESS offer ID: 360276

Disclaimer:

The responsibility for the jobs published on this website, including the job description, lies entirely with the publishing institutions. The application is handled uniquely by the employer, who is also fully responsible for the recruitment and selection processes.

 

Please contact support@euraxess.org if you wish to download all jobs in XML.